Matches in SemOpenAlex for { <https://semopenalex.org/work/W182584322> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W182584322 endingPage "14" @default.
- W182584322 startingPage "S7" @default.
- W182584322 abstract "The development of anti-immunoglobulin E (IgE) antibodies for prophylactic and therapeutic applications in allergic diseases has taken nearly 20 years. Limited usage has been approved for allergic asthma. The usage in other allergic indications is in active development and may take an additional 5-10 years. The current therapeutic anti-IgE, which includes two humanized recombinant monoclonal antibodies, is the result of rational drug design, taking into consideration the structural features of IgE and membrane-bound IgE (mIgE) and various techniques collectively referred to as antibody engineering. Unlike ordinary antibodies specific for human IgE, a therapeutic anti-IgE, although capable of binding tightly to free IgE and mIgE, does not bind to IgE bound by the high-affinity IgE.Fc receptors (FcERI) on mast cells and basophils and by the low-affinity IgE.Fc receptors (FcepsilonRII, or CD23) on B cells, granulocytes, and many other cell types. The therapeutic anti-IgE is efficacious in treating allergic patients in whom IgE mediates the major allergic responses. It possesses multiple potential pharmacologic effects; researchers still are uncovering its previously unknown immunoregulatory effects. The human studies of the therapeutic anti-IgE have gradually settled many controversial views relating to IgE, such as the roles of IgE in the pathogenesis of asthma, immune defense, and early and late-phase reactions of allergic responses. Studies on the unique structural mIgE CepsilonmX domain and on the regulatory effects of anti-CepsilonmX monoclonal antibodies will be an area for future investigation of the potential of long-term IgE regulation." @default.
- W182584322 created "2016-06-24" @default.
- W182584322 creator A5056671813 @default.
- W182584322 date "2006-05-26" @default.
- W182584322 modified "2023-09-25" @default.
- W182584322 title "Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E." @default.
- W182584322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16722326" @default.
- W182584322 hasPublicationYear "2006" @default.
- W182584322 type Work @default.
- W182584322 sameAs 182584322 @default.
- W182584322 citedByCount "3" @default.
- W182584322 countsByYear W1825843222015 @default.
- W182584322 countsByYear W1825843222016 @default.
- W182584322 crossrefType "journal-article" @default.
- W182584322 hasAuthorship W182584322A5056671813 @default.
- W182584322 hasConcept C141105273 @default.
- W182584322 hasConcept C159654299 @default.
- W182584322 hasConcept C203014093 @default.
- W182584322 hasConcept C2778564945 @default.
- W182584322 hasConcept C34814297 @default.
- W182584322 hasConcept C542903549 @default.
- W182584322 hasConcept C71924100 @default.
- W182584322 hasConcept C8891405 @default.
- W182584322 hasConceptScore W182584322C141105273 @default.
- W182584322 hasConceptScore W182584322C159654299 @default.
- W182584322 hasConceptScore W182584322C203014093 @default.
- W182584322 hasConceptScore W182584322C2778564945 @default.
- W182584322 hasConceptScore W182584322C34814297 @default.
- W182584322 hasConceptScore W182584322C542903549 @default.
- W182584322 hasConceptScore W182584322C71924100 @default.
- W182584322 hasConceptScore W182584322C8891405 @default.
- W182584322 hasIssue "2 Suppl 1" @default.
- W182584322 hasLocation W1825843221 @default.
- W182584322 hasOpenAccess W182584322 @default.
- W182584322 hasPrimaryLocation W1825843221 @default.
- W182584322 hasRelatedWork W101055187 @default.
- W182584322 hasRelatedWork W1541345074 @default.
- W182584322 hasRelatedWork W1545257497 @default.
- W182584322 hasRelatedWork W1565429297 @default.
- W182584322 hasRelatedWork W1679901808 @default.
- W182584322 hasRelatedWork W1987553199 @default.
- W182584322 hasRelatedWork W2003652884 @default.
- W182584322 hasRelatedWork W2020465923 @default.
- W182584322 hasRelatedWork W2027317085 @default.
- W182584322 hasRelatedWork W2052033387 @default.
- W182584322 hasRelatedWork W2113540226 @default.
- W182584322 hasRelatedWork W2582909958 @default.
- W182584322 hasRelatedWork W2614824762 @default.
- W182584322 hasRelatedWork W2915321078 @default.
- W182584322 hasRelatedWork W1503147436 @default.
- W182584322 hasRelatedWork W1516548961 @default.
- W182584322 hasRelatedWork W1537478909 @default.
- W182584322 hasRelatedWork W1563689790 @default.
- W182584322 hasRelatedWork W1604885091 @default.
- W182584322 hasRelatedWork W943371408 @default.
- W182584322 hasVolume "27" @default.
- W182584322 isParatext "false" @default.
- W182584322 isRetracted "false" @default.
- W182584322 magId "182584322" @default.
- W182584322 workType "article" @default.